Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Yosuke Kumekawa"'
Autor:
Mamiko Shiroyama, Shota Fukuoka, Toshiki Masuishi, Atsuo Takashima, Yosuke Kumekawa, Takeshi Kajiwara, Kentaro Yamazaki, Yasuhiro Shimada, Taito Esaki, Akitaka Makiyama, Toshikazu Moriwaki
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract Renal impairment may be associated with an increased risk of hematologic events (AEs) in patients undergoing treatment with trifluridine/tipiracil (FTD/TPI). This study aimed to investigate the specific types of AEs linked to renal impairmen
Externí odkaz:
https://doaj.org/article/e6e3fa6fac624df2a71235a242e51d56
Autor:
Atsuo Takashima, Ken Kato, Eiji Shinozaki, Kensei Yamaguchi, Takeru Wakatsuki, Hiroki Osumi, Naoki Ishizuka, Kota Ouchi, Yosuke Kumekawa, Daisuke Nakano, Manabu Shiozawa, Tadamichi Denda, Ryoichi Sawada, Boku Narikazu
Publikováno v:
BMJ Open, Vol 12, Iss 9 (2022)
Introduction A new concept of ‘NeoRAS wild-type (WT)’, which means conversion of RAS status from RAS mutant to RAS WT after treatment, has been reported. Previous observational and proof-of-concept studies have demonstrated the efficacy of epider
Externí odkaz:
https://doaj.org/article/2594d3e5f4254f72b4e2a4d2cd0fb3c3
Autor:
Hiromichi Nakajima, Shota Fukuoka, Toshiki Masuishi, Atsuo Takashima, Yosuke Kumekawa, Takeshi Kajiwara, Kentaro Yamazaki, Yuji Negoro, Masato Komoda, Akitaka Makiyama, Tadamichi Denda, Yukimasa Hatachi, Takeshi Suto, Naotoshi Sugimoto, Masanobu Enomoto, Toshiaki Ishikawa, Tomomi Kashiwada, Koji Ando, Satoshi Yuki, Hiroyuki Okuyama, Hitoshi Kusaba, Daisuke Sakai, Koichi Okamoto, Takao Tamura, Kimihiro Yamashita, Masahiko Gosho, Toshikazu Moriwaki
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundPrimary tumor location (PTL) is an important prognostic and predictive factor in the first-line treatment of metastatic colorectal cancer (mCRC). Although regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) have been introduced recently,
Externí odkaz:
https://doaj.org/article/1b5c529d863847208161fdacda20bb31
Autor:
Keigo Chida, Daisuke Kotani, Toshikazu Moriwaki, Shota Fukuoka, Toshiki Masuishi, Atsuo Takashima, Yosuke Kumekawa, Takeshi Kajiwara, Kentaro Yamazaki, Masato Komoda, Akitaka Makiyama, Tadamichi Denda, Yukimasa Hatachi, Takeshi Suto, Naotoshi Sugimoto, Masanobu Enomoto, Toshiaki Ishikawa, Tomomi Kashiwada, Koji Ando, Satoshi Yuki, Yoshihiro Okita, Hitoshi Kusaba, Daisuke Sakai, Koichi Okamoto, Takao Tamura, Kimihiro Yamashita, Masahiko Gosho, Yasuhiro Shimada
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Background: The survival benefits of regorafenib (REG) and trifluridine/tipiracil hydrochloride (TFTD) have been demonstrated in chemorefractory patients with metastatic colorectal cancer (mCRC). However, the effects of crossover administration of RE
Externí odkaz:
https://doaj.org/article/62fbb44c692c4df88be7192d21a1ba7b
Autor:
Keitaro Shimozaki, Kenro Hirata, Taro Sato, Maho Nakamura, Kyoko Kato, Hidekazu Hirano, Yosuke Kumekawa, Kaori Hino, Kentaro Kawakami, Yosuke Kito, Toshihiko Matsumoto, Takeshi Kawakami, Masato Komoda, Kengo Nagashima, Yasunori Sato, Kentaro Yamazaki, Shuichi Hironaka, Hiromasa Takaishi, Yasuo Hamamoto, Kei Muro
Publikováno v:
Clinical Colorectal Cancer. 21:339-346
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa68a6c4a0a65007d62f41fec7a6c880
https://doi.org/10.1016/j.clcc.2022.08.002
https://doi.org/10.1016/j.clcc.2022.08.002
Autor:
Mamiko Shiroyama, Shota Fukuoka, Toshiki Masuishi, Atsuo Takashima, Yosuke Kumekawa, Takeshi Kajiwara, Kentaro Yamazaki, Yasuhiro Shimada, Taito Esaki, Akitaka Makiyama, Toshikazu Moriwaki
Background Renal impairment increases the risk of hematologic events (AEs) in patients on trifluridine/tipiracil (FTD/TPI). This study aimed to clarify the specific types of AEs associated with renal impairment in patients with metastatic colorectal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a8997b13855c74238a263c767a79773
https://doi.org/10.21203/rs.3.rs-2852299/v1
https://doi.org/10.21203/rs.3.rs-2852299/v1
Autor:
Naoki Takahashi, Keishi Nakamura, Yosuke Kito, Eiji Kubota, Masako Asayama, Yosuke Kumekawa, Hiroki Hara, Tomohiro Matsushima, Kunihiro Tsuji, Hiromi Kataoka, Akihiro Tsuyada, Yasushi Sasaki, Masashi Idogawa, Takashi Tokino, Takeshi Sawada
Publikováno v:
Journal of Clinical Oncology. 41:172-172
172 Background: Anti-EGFR antibody is recommended as one of the standard treatments in patients with RAS wild-type advanced colorectal cancer (CRC). Few reports have evaluated low-frequency subclones of alterations in EGFR signaling pathway genes in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67316595368de629eb0ac76beecac3ef
https://doi.org/10.1200/jco.2023.41.4_suppl.172
https://doi.org/10.1200/jco.2023.41.4_suppl.172
Autor:
Hiroki Osumi, Naoki Ishizuka, Atsuo Takashima, Yosuke Kumekawa, Daisuke Nakano, Manabu Shiozawa, Tadamichi Denda, Ryoichi Sawada, Kota Ouchi, Takeru Wakatsuki, Boku Narikazu, Ken Kato, Kensei Yamaguchi, Eiji Shinozaki
Publikováno v:
BMJ Open. 12:e063071
IntroductionA new concept of ‘NeoRAS wild-type (WT)’, which means conversion of RAS status from RAS mutant to RAS WT after treatment, has been reported. Previous observational and proof-of-concept studies have demonstrated the efficacy of epiderm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b609fb27a40038838da70e5f7259f18
https://doi.org/10.1136/bmjopen-2022-063071
https://doi.org/10.1136/bmjopen-2022-063071
Autor:
Keitaro Shimozaki, Kenro Hirata, Taro Sato, Maho Nakamura, Kyoko Kato, Hidekazu Hirano, Yosuke Kumekawa, Kaori Hino, Kentaro Kawakami, Yosuke Kito, Toshihiko Matsumoto, Takeshi Kawakami, Masato Komoda, Kengo Nagashima, Yasunori Sato, Kentaro Yamazaki, Shuichi Hironaka, Hiromasa Takaishi, Yasuo Hamamoto, Kei Muro
Publikováno v:
Clinical Colorectal Cancer; Dec2022, Vol. 21 Issue 4, p339-346, 8p
Autor:
Akitaka Makiyama, Yosuke Kumekawa, Taito Esaki, Toshikazu Moriwaki, Kentaro Yamazaki, Yusuke Niisato, Naotoshi Sugimoto, Yasuhiro Shimada, Shota Fukuoka, Atsuo Takashima, Toshiki Masuishi, Takeshi Suto, Tadamichi Denda, Takeshi Kajiwara, Yukimasa Hatachi
Publikováno v:
Anticancer research. 41(4)
Background/aim In later-line treatment of metastatic colorectal cancer (mCRC), trifluridine/tipiracil is often selected because regorafenib is difficult to use in patients with comorbidities such as thrombosis, hemorrhage, or cardiac events. However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb9213eebde135a174a6934344aca90c
https://pubmed.ncbi.nlm.nih.gov/33813435
https://pubmed.ncbi.nlm.nih.gov/33813435